Agilent Technologies will acquire clinical pathology firm Biocare Medical for $950 million in an all-cash deal. The transaction expands Agilent's clinical diagnostics/pathology capabilities and is a strategic M&A move that should modestly affect Agilent's diagnostics revenue mix and could move the company's stock in the near term.
Agilent Technologies will acquire clinical pathology firm Biocare Medical for $950 million in an all-cash deal. The transaction expands Agilent's clinical diagnostics/pathology capabilities and is a strategic M&A move that should modestly affect Agilent's diagnostics revenue mix and could move the company's stock in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
